<DOC>
	<DOCNO>NCT02846545</DOCNO>
	<brief_summary>The primary purpose study determine golimumab preserve beta-cell function child young adult newly diagnose Type 1 Diabetes ( T1D ) .</brief_summary>
	<brief_title>A Study SIMPONI® Arrest Beta-cell Loss Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Be positive least 1 follow diabetesrelated autoantibody obtain study screening : Glutamic acid decarboxylase ( GAD65 ) , islet antigen 2 ( IA2 ) , zinc transporter 8 ( ZnT8 ) , Islet Cell Cytoplasmic Autoantibodies ( ICA ) , Insulin ( obtain within 10 day onset exogenous insulin therapy ) Have peak stimulate Cpeptide level great equal ( &gt; = ) 0.2 picomole per milliliter ( pmol/mL ) follow 4hour Mixedmeal Tolerance Test ( MMTT ) obtain study screen Be medically stable basis physical examination , medical history , vital sign perform screen . If abnormality , must consistent underlie illness study population Females childbearing potential must negative serum ( betahuman chorionic gonadotropin [ betahCG ] ) test screen negative urine pregnancy test Week 0 visit Participants ( legally acceptable representative ) willing able adhere requirement , prohibition , restriction specify protocol Has history significant renal , vascular , pulmonary , gastrointestinal , neurologic , hematologic , rheumatologic , psychiatric disease immune suppression immune deficiency . Has significant cardiovascular disease , include history myocardial infarction , congestive heart failure , angina , abnormal electrocardiogram abnormal stress test Has active infection , prone infection chronic , recurrent opportunistic infectious disease , include limited , chronic renal infection , chronic chest infection ( example [ eg . ] , bronchiectasis ) , sinusitis , recurrent urinary tract infection ( eg. , recurrent pyelonephritis , chronic cystitis ) , Pneumocystis carinii , aspergillosis , latent active granulomatous infection , histoplasmosis , coccidioidomycosis open , drain , infected nonhealing skin wound ulcer Has clinically active infection EpsteinBarr virus ( EBV ) EBV viral load &gt; =10,000 copy per 10^6 peripheral blood mononuclear cell ( PBMCs ) obtain study screening . Has clinically active infection cytomegalovirus ( CMV ) CMV viral load &gt; = 10,000 copy per milliliter ( mL ) whole blood obtain study screen Current prior ( within 30 day screen ) treatment know cause significant , ongoing change course T1D immunologic status , include highdose inhale , extensive topical , systemic glucocorticoid Has autoimmune disease ( eg , rheumatoid arthritis [ RA ] , polyarticular juvenile idiopathic arthritis [ pJIA ] , psoriatic arthritis [ PsA ] , ankylose spondylitis [ AS ] , multiple sclerosis [ MS ] , systemic lupus erythematosus [ SLE ] ) exclude clinically stable autoimmune thyroiditis whether treat untreated Has follow tuberculosis [ TB ] screen criterion : A history latent active TB prior screen ( include limit positive QuantiFERON®TB Gold test ) , sign symptom suggestive active TB upon medical history and/or physical examination , recent close contact person know suspect active TB Has know allergy , intolerance and/or hypersensitivity human immunoglobulin protein , golimumab component excipients</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>